Godavari Drugs Ltd (GODAVARI) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Godavari Drugs Ltd on NSE and BSE, with an AI summary of each filing.
Please find enclosed herewith an intimation regarding change in Corporate Identification Number (CIN) of the company consequent upon alteration of the Object Clause of the Memorandum of Association.
Others (Uncategorized) · 16 Oct 2026, 5:22 pm
Godavari Drugs Updates CIN Following Object Clause Alteration Godavari Drugs Limited has revised its Corporate Identification Number (CIN) from L24230TG1987PLC008016 to L21001TG1987PLC008016. The update follows shareholder approval at the AGM held on 25th Sep'26 to alter the company's Memorandum of Association Object Clause, prompting a business activity reclassification under the National Industrial Classification code. The Ministry of Corporate Affairs formally registered the alteration on 16th Oct'26 in accordance with Section 13(1) of the Companies Act, 2013.
The Board of Directors of Godavari Drugs Limited, at its meeting held on 14th October, 2026, approved availing of Working Capital Limits up to Rs. 340 Million from ICICI Bank Limited and ....
Others (Uncategorized) · 14 Oct 2026, 10:06 pm
Godavari Drugs Approves Rs 340 Million Working Capital Facility From ICICI Bank Godavari Drugs Limited's Board of Directors approved availing working capital credit facilities aggregating up to Rs 340.00 Mn from ICICI Bank Ltd on 14th Oct'26. The limits include provisions for temporary overdrafts or accommodations alongside security creation as outlined in the bank's arrangement letter dated 12th Oct'26. Managing Director Mukund Kakani has been authorized to execute the necessary documentation. The company confirmed that the facility remains within previously approved shareholder borrowing limits under Section 180(1)(c) of the Companies Act, 2013.
Voting Results & Scrutinizer Report of 38th Annual General Meeting of Godavari Drugs Limited
Annual General Meeting · 26 Sept 2026, 11:27 pm
Proceedings of the 38th AGM held on 25.09.2026
Annual General Meeting · 25 Sept 2026, 10:13 pm
We hereby inform that the company has dispatched a physical letter to the shareholders whose email addresses are not registered with the company/RTA/Depositories/DP. The Letter contains ....
Annual Report · 03 Sept 2026, 7:38 pm
The Company informed that the 38th AGM of the Company is scheduled to be held on Friday, the 25th Sep 2026 at 03.00 pm through Video Conferencing/ other Audio Visual means in accordance ....
Others (Uncategorized) · 01 Sept 2026, 10:24 pm
Notice of 38th AGM to be held on 25th Sep 2026 at 03.00 p.m. through Video Conferencing/Other Audio Visual Means in accordance with the relevant circulars issued by the MCA and SEBI.
Annual General Meeting · 01 Sept 2026, 10:18 pm
Amendment to MOA of the company was approved by Board of Directors. The Proposed change in MOA of the company is subject to necessary approvals from Ministry of Corporate Affairs, Shareholders ....
Others (Uncategorized) · 01 Sept 2026, 4:31 pm
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we inform that the Board of Directors at its meeting held on 31st August, 2026 approved the following: 1. Alteration of the ....
Others (Uncategorized) · 01 Sept 2026, 12:26 am
Submission of Statement on Deviation or Variation in uitilisation of Funds for the quarter ended 30 june 2026
Others (Uncategorized) · 17 Aug 2026, 5:10 pm
Godavari Drugs Reports No Deviation in Fund Utilization for Q1FY27 Godavari Drugs reported no deviation in the utilization of funds for the quarter ended 30 Jun'26. The company raised ₹4,411.73 lakh via a preferential issue on 18 Mar'26. Of the total raised, ₹763.27 lakh was utilized towards capital expenditure for manufacturing APIs and intermediates, against a total allocation of ₹11,000 lakh for this purpose. No funds were used for working capital or repayment of unsecured loans during the quarter. The filing confirms adherence to the stated objectives of the fundraise.
Board of Directors of the Company in its meeting held on Friday, 14th August, 2026 at 11.45 A.M. approved and passed the resolution for allotment of Equity Shares on conversion of 7,86,690 ....
Others (Uncategorized) · 14 Aug 2026, 6:35 pm
Godavari Drugs Allots Equity Shares to Promoters via Warrant Conversion Godavari Drugs announced on 14th Aug'26 the allotment of 7,86,690 equity shares to its promoter group upon conversion of warrants. The shares were issued at a price of Rs. 89/- each. This follows the receipt of the balance 75% payment, aggregating to Rs. 5.25 Cr. Consequently, the company's paid-up equity capital has increased from Rs. 10.13 Cr to Rs. 10.91 Cr, resulting in equity dilution. A total of 15,73,375 warrants remain outstanding for potential future conversion.
Submission of Un-Audited Standalone Financial Results for the Quarter ended as on June 30, 2026
Financial Result · 14 Aug 2026, 6:29 pm
Godavari Drugs Q1 FY27: Profit Rises YoY Despite Revenue Dip Godavari Drugs reported a net profit of ₹110.91 lakhs for Q1 FY27, a 6.6% YoY increase from ₹104.06 lakhs in Q1 FY26. However, profit declined 14.1% QoQ. Revenue from operations for the quarter ended 30th Jun'26 was ₹2,795.72 lakhs, up 17.4% YoY but down 15.7% QoQ. Total expenses decreased sequentially to ₹2,693.09 lakhs. Basic EPS for the quarter stood at ₹1.10, down from ₹1.71 in the prior quarter but lower than the ₹1.38 reported in the same quarter last year.
Submission of Un-Audited Standalone Financial Results for the Quarter ended as on June 30, 2026 and Allotment of Equity Shares on conversion of 7,86,690 (Seven Lakhs Eighty-Six Thousand ....
Outcome · 14 Aug 2026, 6:24 pm
Godavari Drugs Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 2,796 (+17.4% YoY | -15.7% QoQ) ■ EBITDA: 252 (-13.2% YoY | -14.5% QoQ) ■ EBITDA Margin (%): 9.0 (-318 bps YoY | +13 bps QoQ) ■ PAT: 111 (+6.6% YoY | -14.1% QoQ) ■ EPS (INR): 1.10 (-20.3% YoY | -32.9% QoQ)
Godavari Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Update on board meeting - Intimation ....
Intimation · 14 Aug 2026, 5:30 am
Godavari Drugs Corrects Board Meeting Date for Q1FY27 Results Godavari Drugs issued a corrigendum to correct the date for its upcoming Board Meeting. The meeting, scheduled to consider and approve the Un-Audited Financial Results for the quarter ended 30th Jun'26, will now be held on Friday, 14th Aug'26. This corrects the previously stated date of 24th Aug'26, which was a typographical error. All other details from the original 10th Aug'26 intimation remain unchanged.
Godavari Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Un-audited Financial Results ....
Intimation · 14 Aug 2026, 5:30 am
Godavari Drugs Board Meeting to Approve Q1FY27 Results on Aug 24, 2026 Godavari Drugs Limited (BSE: 530317) scheduled a Board of Directors meeting on 24 Aug'26 to consider and approve the un-audited financial results for the first quarter ending 30 Jun'26. In accordance with the company's code of conduct, the trading window for insiders has been closed since 01 Jul'26. The window will reopen 48 hours after the declaration of the Q1 financial results.
Refer Enclosed
Others (Uncategorized) · 27 May 2026, 10:32 pm
Godavari Drugs Confirms No Deviation in Use of Preferential Issue Proceeds Godavari Drugs Limited confirmed no deviation in utilizing funds from its preferential issue for the quarter ended 31 Mar'26. The company raised ₹4,411.73 Lakhs via an equity allotment on 18 Mar'26. Of the total planned capital expenditure of ₹11,000 Lakhs for manufacturing facilities, ₹292.65 Lakhs was utilized during the period. The funds allocated for working capital (₹1,711.73 Lakhs) and repayment of unsecured loans (₹1,600 Lakhs) remained unutilized as of the quarter's end. The audit committee reported NIL comments.
Company in its Board Meeting has approved financial results for period ended 31st march, 2026
Financial Result · 27 May 2026, 10:23 pm
Godavari Drugs Q4FY26 PAT Rises 44.5% YoY; Board Approves New Auditors Godavari Drugs reported a Q4FY26 net profit of ₹129.08 lakhs, up 44.5% YoY, on revenue of ₹3316.31 lakhs, a 30.0% YoY increase. For the full year FY26, net profit was ₹408.91 lakhs, down 6.6% YoY, while revenue fell 6.7% YoY to ₹10580.81 lakhs. FY26 EPS stood at ₹5.43. The board approved the financial results, which received an unmodified audit opinion. Additionally, the board appointed S.K. Lahoti Associates as internal auditors and Bharathula & Associates as cost auditors for FY27. The 38th AGM is scheduled for 25th Sep'26.
We are enclosing Audited Financial Results for the Quarter ended 31st march , 2026 which are approved in Board Meeting which was held today i.e Wednesday, 27th Day of May, 2026
Outcome · 27 May 2026, 10:17 pm
Godavari Drugs Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakhs) ■ Revenue: 3,316 (+30.0% YoY | +49.5% QoQ) ■ EBITDA: 294 (-5.6% YoY | +18.7% QoQ) ■ EBITDA Margin (%): 8.9 (-334 bps YoY | -230 bps QoQ) ■ PAT: 129 (+44.5% YoY | +70.4% QoQ) ■ EPS (INR): 1.64 (+37.8% YoY | +62.4% QoQ)
Godavari Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve the financial results for the ....
Intimation · 27 May 2026, 5:30 am
Godavari Drugs Board Meeting to Approve Q4 FY26 Results on May 27 Godavari Drugs Limited (BSE: 530317) has scheduled a Board of Directors meeting on 27th May'26 to consider and approve the audited standalone financial results for the quarter and financial year ended 31st Mar'26. The company also noted its trading window for insiders has been closed since 1st Apr'26 and will reopen 48 hours after the results are declared. This announcement is a key procedural update for investors ahead of the company's Q4 FY26 earnings release, which will provide insight into its financial performance.
Reply to the BSE Query seeking Clarification on Price Movement
Others (Uncategorized) · 18 Apr 2026, 9:04 pm
Godavari Drugs Clarifies Share Price Movement, Cites Market Conditions In response to a BSE query dated Apr 17, '26, regarding significant share price movement, Godavari Drugs Limited clarified on Apr 18, '26. The company stated it is not aware of any undisclosed price-sensitive information that would necessitate a disclosure under Regulation 30 of SEBI Listing Regulations, 2015. Management asserts that all required disclosures have been made and attributes the recent share price volatility entirely to market conditions, over which it has no control. The company confirmed its continued compliance with all disclosure requirements.
The Exchange has sought clarification from Godavari Drugs Ltd on April 17, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....
Others (Uncategorized) · 18 Apr 2026, 1:14 am
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Priyanka Jaju, Mukund Kakani, Prashant Shrimal, ....
Acquisition/ Disposal of Shares · 23 Mar 2026, 10:33 pm
Godavari Drugs Promoters Acquire Shares and Warrants via Preferential Allotment Multiple promoter group entities of Godavari Drugs acquired shares and convertible warrants via preferential allotment on 18th Mar'26. Key acquisitions include 469,000 warrants by Mukund Kakani, 423,000 warrants by Sushma Kakani, and 300,000 warrants by Kamala Jaju. Additionally, Prashant Shrimal acquired 112,360 equity shares. This move increases the promoter group's aggregate holding, signaling confidence. The acquisitions were disclosed under SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011, with the company notifying the BSE on 23rd Mar'26.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prashant Shrimal
Acquisition/ Disposal of Shares · 23 Mar 2026, 5:52 pm
Godavari Drugs Promoter Group Acquires Shares via Preferential Allotment Prashant Shrimal, a member of the Promoter Group of Godavari Drugs Ltd, acquired 1,12,360 equity shares via a preferential allotment on 18 Mar'26. This transaction increases his holding to 1.11% of the company's total share capital and 0.90% on a fully diluted basis. Post-allotment, the company's total equity share capital increased to Rs. 10,12,74,350.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mohit Jaju
Acquisition/ Disposal of Shares · 21 Mar 2026, 12:08 am
Godavari Drugs Promoter Acquires Warrants via Preferential Issue Promoter Mohit Jaju acquired 400,065 convertible warrants in Godavari Drugs Limited via a preferential allotment on 18th Mar'26. This acquisition increases his potential diluted shareholding in the company from 7.1% to 7.29%. Following the transaction, Mr. Jaju holds 535,000 equity shares and 400,065 warrants. The promoter group's total holding now stands at 5.28% of the total voting capital and 7.29% on a fully diluted basis, signaling increased promoter conviction in the company.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kamala Jaju
Acquisition/ Disposal of Shares · 21 Mar 2026, 12:04 am
Godavari Drugs: Promoter Kamala Jaju Acquires Convertible Warrants Promoter Kamala Jaju acquired 3,00,000 convertible warrants in Godavari Drugs Limited via a preferential issue on 18th Mar'26. This acquisition represents 2.40% of the total diluted share capital. Post-acquisition, the promoter's total holding (shares and warrants) increased to 9.69% of the diluted share capital, up from 12.08% of the pre-issue total share capital. The company's total diluted share capital post-issue stands at Rs. 12,48,75,000, comprising 1,24,87,500 equity shares of Rs. 10 each.